You just read:

VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder

News provided by

VistaGen Therapeutics

Oct 08, 2019, 08:30 ET